hepatocellular carcinoma research hub

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis

This study is testing a new medicine, AZD4831, for people with a liver condition called NASH. We want to see if it's safe, how well people tolerate it, and if it helps reduce inflammation in the liver after 12 weeks compared to a dummy medicine.